Trial Profile

A Phase 2 trial of YTX-7739 in patients with Parkinson's disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YTX 7739 (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors Kineta; TuHURA Biopharma; Yumanity Therapeutics

Most Recent Events

30 Jun 2025 According to TuHURA Biosciences media release, Kineta has been acquired and merged into TuHURA Biosciences.
19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
24 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com